These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11114868)

  • 1. Current perspectives for treatment of breast cancer.
    Bunnell C
    Breast Cancer; 2000; 7(4):380-8. PubMed ID: 11114868
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab in inflammatory breast cancer.
    Mehta RS; Schubbert T; Kong K
    Ann Oncol; 2008 Oct; 19(10):1815-7. PubMed ID: 18711028
    [No Abstract]   [Full Text] [Related]  

  • 3. Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
    Ferretti G; Felici A; Papaldo P; Carlini P; Fabi A; Cognetti F
    Oncologist; 2006 May; 11(5):533; author reply 534. PubMed ID: 16720857
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer.
    Ahluwalia MS; Daw HA
    J Clin Oncol; 2005 Oct; 23(30):7759-60; author reply 7760-1. PubMed ID: 16234551
    [No Abstract]   [Full Text] [Related]  

  • 5. Herceptin in the adjuvant setting: phase III trials begin.
    McNeil C
    J Natl Cancer Inst; 2000 May; 92(9):683-4. PubMed ID: 10793100
    [No Abstract]   [Full Text] [Related]  

  • 6. [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].
    Ficorella C
    Tumori; 2001; 87(1 Suppl 2):S10-8. PubMed ID: 11357872
    [No Abstract]   [Full Text] [Related]  

  • 7. HER2 and response to paclitaxel in node-positive breast cancer.
    Roukos DH
    N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18193530
    [No Abstract]   [Full Text] [Related]  

  • 8. Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.
    Oncology (Williston Park); 2005 Jun; 19(7):851, 862. PubMed ID: 16053034
    [No Abstract]   [Full Text] [Related]  

  • 9. HER2 and response to paclitaxel in node-positive breast cancer.
    Ferretti G; Felici A; Cognetti F
    N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18184969
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2 and response to paclitaxel in node-positive breast cancer.
    Nash I
    N Engl J Med; 2008 Jan; 358(2):198; author reply 198-9. PubMed ID: 18193532
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long-term survival of a breast cancer patient with liver metastasis treated with trastuzumab and Paclitaxel].
    Ota Y; Ishikawa T; Yamada A; Shimizu D; Hasegawa S; Chishima T; Endo I
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1091-4. PubMed ID: 20567114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
    Fornier M; Esteva FJ; Seidman AD
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of trastuzumab to chemotherapy produces 50% increase in survival in patients selected by FISH.
    Oncology (Williston Park); 2001 Oct; 15(10):1345, 1364. PubMed ID: 11702961
    [No Abstract]   [Full Text] [Related]  

  • 15. [Combined chemotherapy with molecular-targeted agent for breast cancer].
    Ito Y; Miura H
    Gan To Kagaku Ryoho; 2008 May; 35(5):731-6. PubMed ID: 18487908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application].
    Campone M; Merlin JL; Fumoleau P
    Bull Cancer; 2003 Jul; 90(7):614-22. PubMed ID: 12957803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac dysfunction in clinical trials of trastuzumab.
    Page E; Assouline D; Brun O; Coeffic D; Fric D; Winckel P
    J Clin Oncol; 2002 Oct; 20(19):4119; author reply 4120. PubMed ID: 12351610
    [No Abstract]   [Full Text] [Related]  

  • 18. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy.
    Bader AA; Schlembach D; Tamussino KF; Pristauz G; Petru E
    Lancet Oncol; 2007 Jan; 8(1):79-81. PubMed ID: 17196514
    [No Abstract]   [Full Text] [Related]  

  • 19. [A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].
    Mizuno Y; Chin K; Ando N; Oike E
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1293-6. PubMed ID: 16969027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
    Altundag K; Baptista MZ
    Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.